Cargando…
Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases
Rare diseases pose a global challenge, in that their collective impact on health systems is considerable, whereas their individually rare occurrence impedes research and development of efficient therapies. In consequence, patients and their families are often unable to find an expert for their affli...
Autores principales: | Papasavva, Panayiota, Kleanthous, Marina, Lederer, Carsten W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469594/ https://www.ncbi.nlm.nih.gov/pubmed/30945166 http://dx.doi.org/10.1007/s40291-019-00392-3 |
Ejemplares similares
-
Disruptive Technology: CRISPR/Cas-Based Tools and Approaches
por: Patsali, Petros, et al.
Publicado: (2019) -
CRISPR Editing Enables Consequential Tag-Activated MicroRNA-Mediated Endogene Deactivation
por: Papasavva, Panayiota L., et al.
Publicado: (2022) -
Relative and Absolute Quantification of Aberrant and Normal Splice Variants in HBB(IVSI−110 (G > A)) β-Thalassemia
por: Patsali, Petros, et al.
Publicado: (2020) -
Catching Them Early: Framework Parameters and Progress for Prenatal and Childhood Application of Advanced Therapies
por: Lederer, Carsten W., et al.
Publicado: (2022) -
Genetic Modifiers at the Crossroads of Personalised Medicine for Haemoglobinopathies
por: Stephanou, Coralea, et al.
Publicado: (2019)